GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (BOM:532872) » Definitions » Net Cash per Share

Sun Pharma Advanced Research Co (BOM:532872) Net Cash per Share : ₹0.00 (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Sun Pharma Advanced Research Co's Net Cash per Share for the quarter that ended in Dec. 2024 was ₹0.00.

The historical rank and industry rank for Sun Pharma Advanced Research Co's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Sun Pharma Advanced Research Co was 385.22. The lowest was 46.27. And the median was 89.60.

BOM:532872's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.56
* Ranked among companies with meaningful Price-to-Net-Cash only.

Sun Pharma Advanced Research Co Net Cash per Share Historical Data

The historical data trend for Sun Pharma Advanced Research Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharma Advanced Research Co Net Cash per Share Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.78 -14.59 -8.68 2.62 -7.15

Sun Pharma Advanced Research Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.15 - - -

Competitive Comparison of Sun Pharma Advanced Research Co's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's Price-to-Net-Cash falls into.


;
;

Sun Pharma Advanced Research Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Sun Pharma Advanced Research Co's Net Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as

Net Cash per Share (A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1571.308-3892.868-0)/324.522
=-7.15

Sun Pharma Advanced Research Co's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Pharma Advanced Research Co  (BOM:532872) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Sun Pharma Advanced Research Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Pharma Advanced Research Co Business Description

Traded in Other Exchanges
Address
Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines